Mizuho Maintains Outperform on Assembly Biosciences, Raises Price Target to $45
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and raises the price target from $40 to $45.
Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and raises the price target from $40 to $45.